Myocardial Protection and Cardioplegia

Myocardial protection is the set of strategies used to limit injury to the heart muscle while its coronary blood supply is interrupted during cardiac surgery. The central method is cardioplegia: the deliberate, reversible arrest of the heart, usually with a potassium-rich solution that stops it in diastole and sharply lowers its metabolic demand, so that the myocardium tolerates the ischaemic period of aortic cross-clamping.

Definition

Cardioplegia is the induced, reversible electromechanical arrest of the heart - typically achieved with a high-potassium solution - used to reduce myocardial metabolic demand and protect the muscle from ischaemic injury while the aorta is cross-clamped during cardiac surgery.

Scope

This topic covers the rationale for protecting the arrested heart, the principle of cardioplegic arrest, the main solution types (crystalloid versus blood), and the routes and temperature of delivery. It is an educational reference and deliberately omits dosing, formulations, and protocols; it is not clinical or operative guidance.

Core questions

• Why does the myocardium need protection during cardiac surgery?
• How does a cardioplegic solution arrest the heart and lower its metabolic demand?
• What distinguishes crystalloid from blood cardioplegia?
• How do delivery route and temperature affect protection?

Key concepts

• Induced reversible cardiac arrest
• Hyperkalaemic diastolic arrest
• Reduction of myocardial oxygen demand
• Ischaemia-reperfusion injury
• Crystalloid versus blood cardioplegia
• Antegrade and retrograde delivery
• Cold versus warm cardioplegia

Mechanisms

When the aorta is cross-clamped, coronary perfusion stops and the beating myocardium would rapidly deplete its energy stores and accumulate ischaemic injury. Cardioplegia counters this by arresting the heart: a solution with a high potassium concentration depolarizes the myocyte membrane and holds the heart in diastolic standstill, eliminating the metabolic cost of contraction. Lowering temperature (cold cardioplegia) further reduces metabolic rate, while warm cardioplegia aims to maintain aerobic metabolism during arrest. Solutions may be crystalloid or blood-based, the latter adding oxygen-carrying capacity and buffering; they can be delivered antegrade through the aortic root or coronary ostia, or retrograde through the coronary sinus when antegrade flow is impaired. Reperfusion at the end of the cross-clamp period reintroduces flow, and limiting reperfusion injury is part of the protection strategy.

Clinical relevance

Myocardial protection determines how well the heart recovers function after the ischaemic period of an operation, and the concepts are central to understanding cardiac surgical physiology. This entry describes the principles of protection; it does not specify solutions, concentrations, or protocols and is not a basis for individual treatment.

Evidence & guidelines

The field rests on decades of experimental and clinical work, from the European origins of cardioplegia and the St Thomas' Hospital solutions to Buckberg's development of blood cardioplegia and trials of warm versus cold and antegrade versus retrograde delivery. Comparative studies of solution type, temperature, and route continue, and no single approach is universally regarded as superior across all settings.

History

The idea of arresting the heart for surgery dates to mid-twentieth-century experiments, and modern cardioplegia matured in the 1970s and 1980s through European work on crystalloid solutions, exemplified by the St Thomas' Hospital cardioplegic solutions developed by Hearse, Braimbridge, and colleagues. Buckberg's introduction of blood cardioplegia and the subsequent exploration of warm, cold, antegrade, and retrograde strategies shaped the contemporary repertoire of myocardial protection.

Debates

Blood versus crystalloid cardioplegia

Blood cardioplegia adds oxygen-carrying capacity and buffering, while crystalloid solutions are simpler; the relative benefit varies with context and the comparison remains a long-running discussion in myocardial protection.

Warm versus cold and intermittent versus continuous delivery

Temperature and timing of cardioplegia trade hypothermic metabolic suppression against maintained aerobic metabolism and surgical field visibility, and approaches such as intermittent antegrade warm blood cardioplegia illustrate the competing strategies.

Key figures

• Gerald Buckberg
• David Hearse
• Mark Braimbridge
• Antonio Maria Calafiore

Seminal works

• buckberg-1989
• braimbridge-1990
• chambers-1989

Frequently asked questions

Why is the heart deliberately stopped during cardiac surgery?

Stopping the heart in diastole with a cardioplegic solution removes the metabolic cost of contraction and gives the surgeon a still, bloodless field, allowing the muscle to tolerate the period when its own blood supply is clamped off.

What is the difference between blood and crystalloid cardioplegia?

Crystalloid cardioplegia is a salt-based solution, whereas blood cardioplegia mixes the arresting solution with the patient's blood to add oxygen-carrying capacity and buffering. Both are used; the choice depends on the surgeon's strategy and the clinical context.